Neural crest cell (NCC)-derived mesenchymal cells (Mes) and endothelial cells are two key cell types essential for thymus formation, establishing the thymus vasculature. The vasculature serves as the entry site for T lymphocyte precursors or early thymus progenitors (ETPs), generated in fetal liver and bone marrow, to the thymic cortex. Endothelial cells form a cushion around the developing arterioles and veins, with the perivascular space comprising collagen fibers. Perivascular cells include pericytes and vascular smooth muscle cells (VSMCs) (40). The thymus anlage forms as Mes first localize around the 3^rd PP (23). Mes release BMP4 and Sonic Hedgehog (SHH) in a spatially and temporally defined manner, initiating the patterning of the thymus and parathyroid regions, respectively (1, 7). Fibroblast growth factors (FGF7 and FGF10) and insulin growth factors (IGF1 and IGF2), secreted by Mes, are bound by the corresponding FGF- (FGFR2IIIb) and IGF- receptors (IGFR1) expressed on immature TECs, providing growth signals to the latter (41, 42). Multiple FGFs (FGF3, FGF8, FGF10, FGF15) are differentially expressed in a regionalized manner (43). Dysregulated activation of the FGF pathway leads to thymus hypoplasia, revealing the importance of temporal control of FGF expression levels (42, 43). A key role for Mes in thymus development has been shown using several distinct experimental approaches. First, extirpation of the cephalic neural folds in chick embryos (stage 9), a technique that depletes NCC-mesenchymal cells, results in thymus hypoplasia/aplasia (44). Second, mechanical removal of the Mes capsule from murine e12.5 thymuses causes a stunted expansion of the lobes when placed in culture (41, 45). Extraction of the capsule also limits tissue expansion when the thymus is grafted under the adult kidney capsule, despite adult kidney mesenchyme surrounding the tissue (41, 46–48). In the capsule stripped thymuses, T cell development is normal, as only a reduced cell number is noted relative to controls (41). Epidermal growth factor (EGF) addition can replace thymic mesenchyme to induce the lobulation of e13 embryonic thymuses, however this can occur in the absence of thymocytes (49, 50). Third, 22q11.2 deletion syndrome (often termed DiGeorge syndrome) causes congenital hypoplasia of the thymus (51, 52). The primary reason is a failure of Mes to support tissue expansion, established using murine models of the syndrome. Mesenchymal cells also induce MHC class II molecules on epithelial cells (49).

As the two thymus lobes expand, they pair and descend along the right and left subclavian arteries. The descent (between e11.0 and e12.5) involves erythropoietin-producing hepatocellular carcinoma (EPH) ligand-EPH receptor (EPHR) coupled Mes and TEC signaling (53). The Mes cells that differentiate into pericytes during embryogenesis are retained post-birth and into adulthood, determined by fate mapping neural crest cells with an embryonic specific Sox10-driven Cre expression (23, 54, 55). Such pericytes secrete sphingosine 1 phosphate (S1P) at the corticomedullary junction, which is needed to recruit thymus progenitor cells and enable the egress of the mature thymocytes into the circulation (38). Most studies have grouped the Mes populations collectively, principally based on the expression of Pdgfrα and/or fate mapping. More recent deep sequencing technologies, particularly single cell RNA sequencing is revealing a more complex heterogeneity among Mes cells (56, 57). Five Mes subtypes are evident in the developing embryonic thymus ( Table 2 ), among these are pericytes, vascular smooth muscle cells and fibroblasts. Recent studies have revealed some heterogeneity between the capsular and medullary fibroblasts (58). Comparing human thymuses from fetal stages as well as postnatally by scRNA sequencing reveal 3 Mes subtypes; Fibroblast type 1 (PDGFRA, COLEC11, C7, GDF10), Fibroblast type 2 (PDGFRA, PI16, FN1, FBN1) and VSMCs (ACTA2) ( Table 2 ) (57). Fibroblast types 1 and 2 (Fb1 and Fb2) are localized in peri lobular or interlobular positions, respectively. Fb1 cells express genes such as Aldehyde dehydrogenase 1A2 (ALDH1A2), which is needed for retinoic acid (RA) production, a morphogen that supports TEC development (47). Fb2 are often associated with large blood vessels lined with VSMCs. Fb2 express extracellular matrix protein and semaphorins that aid in vascular development (57). Notably, the fibroblast composition changes over time, with a Fibroblasts type 1 (Fb1) population prevalent in early developmental stages, while type 2 (Fb2) dominates in post-natal and adult thymus tissue (57). The antigens produced by these fibroblast subsets have a key role in central tolerance (58).

Endothelial cells are a second, critical non-hematopoietic cell type, needed for effective thymopoiesis. ScRNA sequencing data suggests the existence of one major endothelial cell type (56, 57, 59). As described in an earlier section, these cells form the vasculature/blood vessel network in the thymus. Of critical relevance to the specification of the embryonic thymus, some endothelial cells differentiate into TECs. The scRNA sequencing studies coupled with bioinformatics screens for paired ligand-receptor interactions between endothelial cells and thymocyte progenitors also reveals important contributions of MADCAM1-CD44, CFH-SELL, and CD34-SELL in thymopoiesis ( Table 1 ). In adult tissues, endothelial cells regulate thymocyte homing via the lymphotoxin β receptor (LTβR) (60). The ligands for LTβR, lymphotoxin and LIGHT, are produced by mature T cells to activate endothelial-regulated homing functions. In adult thymus tissues following radiation-induced damage, the endothelial cells secrete BMP4 to support tissue regeneration (61). This is partly due to BMP4 enhancement of FOXN1 expression (61). It is likely that the embryonic endothelial cells also produce BMP4 in developing thymuses. In the post-natal thymus, the endothelial cells in the cortical region express high levels of claudin-5, which limits cell entry. This contrasts the endothelial cells in the cortical medullary junction (CMJ) and medulla, where many of the cells have lost claudin-5 expression, enabling T cell migration and egress following positive selection (62).

TECs are derived from endothelial cells around e10.5, beginning with the formation of immature bi-potent thymus epithelial cell (TEC) precursors (63, 64). These are defined by the expression of Cytokeratin 8, Cytokeratin 14, beta5t (encoded by Psmb11) and PLET1 (65). Immature TEC growth is sustained by various growth factors secreted by Mes, including FGFs and IGFs, as described above ( Table 1 ). As the thymus and parathyroids coordinately expand, the immature TECs express high levels of E-cadherin, which facilitates the separation of the two tissues (53). The first identification of TEC progenitors revealed that mTECs and cTECs share a common origin (66, 67). Later complementary studies reported that embryonic TEPs expressing cortical markers can generate both cTECs and mTECs (68–70). The essential functional roles of TECs are mediated by FOXN1 (12, 71). FOXN1 is expressed in TECs following the initial specification of the thymus (10). The importance of FOXN1 in TECs was best revealed with spontaneously arising murine Foxn1 mutations along with the identification of humans who had autosomal recessive FOXN1 mutations, resulting in a Nude/SCID phenotype (12, 72–77). The Nude designation arises from alopecia universalis and nail dystrophy (75). In the skin, loss of FOXN1 prevents sufficient expression and deposition of keratins along the hair shaft, causing the hair follicle to curl and break instead of extruding through the epidermal layers (78). SCID arises because of an inability of the TECs to differentiate and expand without FOXN1, causing a block in T cell development at the early DN stage of thymopoiesis [reviewed in (13, 14, 79, 80)]. A key advance in understanding how FOXN1 controls TEC functions was the identification of its transcriptional targets by chromatin immunoprecipitation coupled with DNA sequencing. Using a FLAG-tagged Foxn1 BAC transgenic mouse line, a consensus nucleotide binding site of GACGC was identified (14). Among the ~500 or so direct targets of murine Foxn1 are chemokines and Notch ligands, Ccl25, Cxc112 and DLL4, respectively (14, 81). Other important gene targets include peptidases (e.g., Tasp1), proteases (e.g., Prss16), proteasome complex components (e.g., Psmb4, Psmb9, Psmb10, Psmb11, Psmb16, Psma4), peptide transporters required for MHC class I peptide presentation (e.g., Tap2), many keratins and Cd83 (14, 78, 81). Psmb11 encodes beta5t, a catalytic subunit of the thymus-specific proteasome (thymoproteome), generating peptides that are bound by MHC class I to support the positive selection of CD8⁺ T cells (81, 82). CD83 is required for the development of most CD4⁺ T cells (83). FOXN1 positively regulates itself, binding to the GACGC sequence present in its own promoter (78, 84, 85). In the skin, the Hoxc13 transcription factor positively regulates Foxn1 expression (78). Mutations in human HOXC13 diminish FOXN1 levels in the skin, causing ectodermal dysplasia, characterized by atrichia and nail dystrophy (86). Several Wnt glycoproteins also positively regulate Foxn1 expression (87). An analysis of conserved nucleotide sequences close to the Foxn1 target sequence reveals enrichment of TAp63 (one of two p63 gene transcription isoforms) and CREB binding sites. Notably, TAp63 participates in TEC homeostasis (88–90).

As immature TECs expand, they develop into two major subsets, designated as cortical or medullary TECs based on their location within the thymus. Cortical TECs are defined by the expression of Cathepsin L, TSPP and PSMB11 [reviewed in (91)]. These cells support the recruitment of early thymus progenitors from the blood via selected chemokines (CCL21, CCL25) as well as the progression of thymocytes from the DN to DP stages of thymopoiesis (CCL19, CCL25, CXCL12). CCL9, CCL21, CCL25, CCL12, positively regulated by FOXN1, provide directional cues for developing thymocytes (39, 92). DLL4 levels, which are much higher on cTECs than mTECs, signal immature thymocytes via Notch to progress from the DN to DP subset (25, 93). The conditional targeting of DLL4 in TECs leads to a severe failure of T cell development at the DN1 stage of early DN thymocyte progression. Likewise, the elimination of the receptor (Notch 1) for DLL4 on hematopoietic progenitor cells prevents T cell development (94). Cortical TECs also secrete IL7, a cytokine that stimulates DN thymocyte growth via the IL7Ra/IL2Rg receptor (24, 26).

The medullary regions of the thymus form during embryogenesis as small pockets that expand and coalesce into the larger clusters present post-natally. These mTECs differentiate/proliferate following interactions with mature SP thymocytes. In the embryonic period, Notch signaling is needed for the formation of mTECs, with RANK-mediated signaling more important for the mTECs post-natally (95, 96). The differentiation involves CD4 SP thymocyte expression of Notch and/or RANK in combination with CD40L and EGFR (95–101). Once formed, mTECs are defined by the expression of Cathepsin S, CD40, CCR7 ligand (CCL19/CCL21) and AIRE [reviewed in (91)]. Medullary TECs mediate negative selection of SP T cells along with the positive selection of T regulatory cell subsets (102, 103) [reviewed in (30, 32)]. One of the mTEC subsets produces the chemokines CCL19 and CCL25 to attract positively selected, CCR7 expressing thymocytes into the medullary region (104). Mice lacking the lymphotoxin beta receptor fail to develop these mTECs (105). As the SP thymocytes traffic through the medullary region, they interact with a second subset of mTECs, defined by the expression of the autoimmune regulator (AIRE) gene. AIRE enforces the expression of “tissue-restricted” proteins that eliminate autoreactive T cells (33, 106). AIRE facilitates this by releasing RNA polymerase II from promoter regions where this enzyme is stalled, a mechanism normally used to prevents widespread gene expression (107). Mesenchymal epithelial transition factor (c-Met) is expressed by TECs along with early T progenitors. The specific targeting of c-Met in TECs results in age-dependent progressive reduction in TECs number coupled with lower regulatory T cells (108). Similarly, the targeted loss of Shh in TECs reduces both cTEC and mTEC numbers (109). While most studies have detailed the development of cTEC and mTEC from embryonic TEC progenitors, thymus epithelial progenitors have also been identified in adult tissues (110, 111). These adult progenitor populations can give rise to both cortical and medullary TEC subsets (110, 111).

While initial characterizations of TECs relied on cell surface protein expression and fate mapping to define subsets, scRNA sequencing is revealing many additional epithelial and TEC subsets. For example, an analysis of embryonic day 13-13.5 fetal thymuses, when 80% of the cells are stromal (Mes, TEC, endothelial), reveal 6 distinct epithelial subsets ( Table 2 ). Multiple other studies have revealed different TEC populations at different developmental stages (112–116). Among these are 2 subsets of immature TECs along with cTEC^lo and cTEC^hi subsets, with the lo and hi referring to MHC class II levels. At e13.-13.5 stage, no mTECs are evident. A 5^th epithelial subset expresses parathyroid hormone (PTH), suggesting either the presence of some parathyroid TECs or the existence of a bi-functional TEC. The 6^th epithelial subset (E-6) expresses Nkx2.1, which may be a thyroid or parathyroid precursor cell type. ScRNA sequencing of human thymuses obtained at gestational weeks 19 and 23 (e14.5-e16.5 in murine embryos) and postnatal samples from 6-day old newborn (e20) and an infant (10 months) reveals 3 major epithelial groups broken down into 9 subclusters (57). Two clusters are categorized as cTECs based on the characteristic genes (PSMB11, PRSS16, CCL25). One cluster is the cTEC^lo, which is rapidly proliferating based on Ki67⁺ expression. The second cluster is the cTEC^hi. mTECs are also evident in the embryonic tissues at this developmental stage, and split into 3 distinct subgroups partly defined by the levels of HLA class II. These are mTEC^lo (CLDN4 and lower levels of HLA class II), mTEC^hi (SPIB, AIRE, FEZF2, higher levels of HLA class II), and corneocyte-like mTECs (KRT1, IVL) (56). Cells in the mTEC^lo cluster express high levels of the chemokine CCL21, similar to the CCL21-expressing post-natal mTEC^lo population described in mice (105). Another epithelial cluster, marked by FOXN1, PAX9, and SIX1, represents immature TECs, and is evident in early developmental stages and remains in postnatal and adult periods. PAX9, and SIX1 are not present in cTECs or mTECs, implicating this cluster as a potential progenitor cell not yet committed to a specific lineage. The additional epithelial clusters identified in human thymuses include neuroendocrine (BEX1, NEUROD1), muscle-like myoid (MYOD1, DES), and myelin⁺ epithelial cell markers (SOX10, MPZ) (56, 57). A mixed medullary/cortical TEC subset (mcTECs), marked by expression of DLK2, is present in late fetal and post-natal human thymuses. Finally, a rare population of tuft-like mTECs is present in human and mouse thymuses, although the genes DCLK1 and POU2F3 used to define this population are not specific to TECs in humans (57).

The various TEC subsets constitute the basic thymic microenvironment. They provide cytokines, chemokines, multiple molecular signals, and cell-to-cell interactions to control thymocyte proliferation, differentiation, and selection. This process leads thymocytes from immature to mature, and in turn, TECs themselves also get maturation from bi-potent epithelial progenitors to functional cTECs and mTECs. The added complexity of many different subsets suggests distinct roles for each in the formation and regeneration of the thymus at different stages.

Post-adolescence, the thymus begins a slow and continuous atrophy (117, 118). Tissue changes include TEC loses, increasing epithelial-to-mesenchymal transitions (EMT) coupled with their differentiation into fibroblasts, adipogenesis, loss of cortical-medullary boundaries, and increases in perivascular spaces (118, 119). Although recruitment of thymus progenitors from the bone marrow is not critically impacted, alternations in T cell development, defects in T cell selection, a contracted TCR repertoire diversity, and reduced egress of naive SP T cells are apparent with aging (120). TEC loses by both EMT and cell death, coupled with the tapered expression of FOXN1 contribute to diminished thymopoiesis (91, 121, 122). In fact, enforced expression of Foxn1 in an aged thymus can restore thymus size and functionality, comparable to that seen with a young thymus (123–125). As the thymus ages, TEC production of IL-7 and FGF21 tapers. FGF21 losses increase intra-thymic adipogenesis and decrease peri-thymic brown adipose tissue (126). The obligate co-receptor for FGF21 is beta-Klotho (KLB), present on the endothelial cells at the corticomedullary junction (126). Reduced signaling via FGF21/KLB comprises endothelial functions. However, KLB-deficient mice have a pronounced thymus hypoplasia not intrinsic to TECs or bone marrow cells, revealing a systemic effect (127). Notably, the KLB-deficient mice have high levels of vitamin D, and thymus hypoplasia is rectified by nutritional restriction of Vitamin D (127).

By mid-age, ectopic adipocytes make up 50% of the thymus (119). Although the adipocytes come from a variety of tissues, mesenchymal transitions via EMT are one proposed source (126). The adipocytes fill the perivascular space and impede entry of thymus progenitor cells (128, 129). Intra-thymically distributed adipocytes also release cytokines, steroids, and hormones that negatively impact thymopoiesis (130–133). Among these are leukemia inhibitory factor (LIF), oncostatin M and IL-6. In mouse models of aging, caloric restriction or systemic administration of Ghrelin improves T cell output by reducing adipogenesis and delaying age-dependent thymic involution (134, 135). EMT further generates an expanding number of fibroblasts within the thymus, increasing fibroblast/TEC ratios (136). Whether these fibroblasts directly contribute to reduced thymus functions, as seen with pulmonary fibrosis, remains to be established (137).

The thymus is extremely stress sensitive, with transient cell losses reaching 90% evident following infections, glucocorticoid treatments, chemotherapy, and radiation exposure (138, 139). Dependent on the severity of the stress and/or the age of the thymus, the damage can be transient (if the damage is only in hematopoietic lineage cells) or permanent (the damage mostly happens in non-hematopoietic lineage cells). Because of this, many clinical interventions are being considered to improve/rejuvenate thymus functions. Among these are cytokines and growth factors that support the non-hematopoietic lineage stromal cell populations and/or developing thymocytes. For example, TEC differentiation/expansion can be improved with IL-22, Keratin growth factor (KGF), EGF, BMP4, RANKL and 2 microRNAs, miR-205 or miR-29a (61, 97, 99, 140–144). Group 3 innate lymphoid (ILC3s) cells in the thymus are one important cell population that facilitate thymus recovery following stress (145). In response to whole body radiation exposure, CD103⁺ thymus dendritic cells release IL-23, which signals the ILC3s to secrete IL-22. The IL-22 receptor (IL-22Ra/IL-10Rb) is principally expressed on cTECs and mTECs, with ligand mediated signaling supporting TEC survival and functionality (141). BMP4, produced by endothelial cells, similarly enhances TEC functions, including an upregulation of FOXN1 along with its downstream targets (61). Additional cytokines, ligands and chemokines that improve T cell development include IL-7, Fms-Like Tyrosine Kinase 3 Ligand (FLT3L), DLL4 and the chemokines CXCL12, CCL19, CCL21, and CCL25 (91, 146–150). In a clinical setting, enhanced thymopoiesis is accomplished by administration of FLT3L, and this is done for patients receiving a bone marrow transplant (151–153). FLT3L increases progenitor cell uptake into the thymus (152). The potential use of the many of the other proteins that support thymopoiesis for clinical treatments requires further validation as many will impact cell populations outside the thymus. Two possible solutions to overcome the pleotropic effects of these various cytokines/chemokines or ligands include direct intrathymic injections, or administration of encapsulated nanoparticles with selectively for the thymus (154, 155). For example, intrathymic injections of Foxn1, consisting of an COOH-terminal TAT transduction domain linked to full-length Foxn1, transiently improves TEC numbers and thymopoiesis in mouse models of hematopoietic stem cell transplantation (155). However, recombinant Foxn1 protein injections into a thymus also result in the protein entering hematopoietic cells, and this can have potentially harmful outcomes (156). Therefore, direct intrathymic injections of post-natally derived TECs or with Foxn1-reprogrammed fibroblasts are alternate strategies with good rejuvenation effects (157, 158). Furthermore, direct intrathymic injections of encapsulated cytokines and/or growth factors and even reprogrammed cells into the thymus may be of therapeutic value.

For individuals with in-born errors of immunity, the clinical treatment options for restoring thymopoiesis are not straightforward. First, an assessment of whether hematopoietic or stromal cell populations are causal to thymus hypoplasia is needed. If genetic mutations are inherent to the hematopoietic cells, bone marrow transplants are an effective clinical treatment (159). However, individuals wherein the non-hematopoietic stromal/epithelial cells of the thymus are impacted, allogeneic thymus tissue transplants remain the only FDA approved therapy (Enzyvant, Inc.) (160–162). For such tissue transplants, the donor thymus is depleted of most hematopoietic cells, leaving a residual mixture of pericytes, endothelial cells, TECs, and some mature CD4⁺ T cells (160). These transplant strategies work for those with a severe T cell lymphopenia. Among the patients who will benefit from such transplants include those with 22q11.2 deletion syndrome (DiGeorge), autosomal recessive FOXN1 mutations, PAX1 mutations, CHARGE (Coloboma, heart defects, anal atresia, growth retardation, genital abnormalities, ear abnormalities) syndrome, or those who had diabetic embryopathies (6, 80, 160). However, the allogeneic transplant approach is not suitable for individuals who retain some thymus functionality, since they will have sufficient peripheral T cell numbers to cause transplant rejection. Among these are patients undergoing chemo ablative therapies. An equally important group to consider are those who had partial or complete thymectomies, often done during restorative cardiothoracic surgeries since the thymus affects surgical access to the heart (163–165). In individuals who were thymectomized at a young age, low naïve peripheral T cell numbers and a reduced TCR repertoire is evident later in life (166, 167). Noteworthy, complete thymectomies are also done for patients with thymomas or the autoimmune disorder Myasthenia gravis (168). Sadly, radiation-mediated thymus ablation was a common standard-of-care treatment for infants during the years 1910-1960 (169, 170). The prevailing medical notion at the time was that a large thymus (which is actually normal) was causing lung compression and/or asthma, leading to sudden infant death syndrome and status thymicolymphaticus (171). Regardless of reasons for why a thymus is “removed”, there are currently no effective strategies for restoring thymopoiesis. Putative solutions emerge from recent advances in thymus regeneration technologies, supported with two lines of evidence. First, it is clear thymus transplants work for patients with a thymus aplasia, as well as with the Nude/SCID mice, where the transplanted tissue supports T cell development (161, 162, 172, 173). This indicates that artificial thymic organoid (ATO) technologies may become an effective clinical approach for tissue regeneration. Second, organoid technologies are rapidly advancing for many types of tissues, although regenerating an effective thymus remains a significant challenge (91).

A quintessential breakthrough for ATOs was the initial development of stromal cell lines (OP9) expressing the Notch ligands Delta-like ligand 1 (DLL1) or DLL4, with both supporting T cell development to the SP stage by engaging Notch on immature thymocytes (174, 175). DLL4 functions better than DLL1 due to the lack of a proline rich domain at the Module at the N-terminus of Notch Ligand (MNNL) (176). This is consistent with the non-redundant role for DLL4 in vivo. An important modification to the OP9 monolayer system was the use a unique murine stromal cell line that re-establishes a 3-d epithelial meshwork upon co-culture with hematopoietic stem and progenitor cells (HSPC) (177). HSPCs can be from either cord- or peripheral- blood or bone marrow (177). While the stromal cell lines were first developed to express human DLL1 (MS5-hDLL1), human DLL4 is now used (177–179). Grown in serum-free culture conditions to eliminate variations caused by serum, human T cell differentiation proceeds to the SP stage in the ATOs (177–179). While the ATO technology is a definite improvement, the organoids are not designed for transplant purposes. Limitations include the low overall numbers of T cells that are generated (1 to 3 x 10⁶ cells), an abnormal CD4/CD8 ratio < 1 and the use of murine cell lines. ATOs can, however, reveal whether a patient with probable in-born error of immunity would need a bone marrow or thymus transplant. For example, patients with mutations in genes affecting stromal cell subsets (mesenchymal, TECs, endothelial) will retain HSPCs capable of thymus development (178, 179). Those with mutations affecting either hematopoietic cell differentiation and or T cell functions (IL2Rg chain, RAG, Artemis, T cell components) will not support T cell development, confirming that a patient will likely need a bone marrow transplants. Notably, the current ATOs now use DLL4 expressing stromal cells (MS5-hDLL4) cultured with patient derived CD34⁺ cells (178, 179).

A third strategic advance for improving thymus organoid technologies is the addition of decellularized thymus scaffolds. Comprising the extracellular matrix from thymuses, these support TEC recolonization and bone marrow cell reconstitution. The reconstituted scaffolds are grafted under the kidney capsule of nude/SCID mice TEC and support T cell development (180–183). Disadvantages of such scaffold approaches include the need for primary human thymus tissues, complex experimental manipulation, and low cell yields. However, recent research has revealed techniques to expand TECs and interstitial cells from human thymuses in large numbers, potentially suitable for clinical approaches (184). Another strategy to generate many functional TECs is to use embryonic fibroblasts, which are reprogrammed with Foxn1 over-expression systems, and are termed inducible TECs. These cells can be reaggregated to generate an ectopic de novo thymus under the kidney capsule in the mouse models (48). Host T cell progenitors seed the de novo thymus-like organ generated by the transplant, and normal thymocyte distributions are observed after 4 weeks. Additionally, typical thymus microstructures are evident in the de novo thymus engrafted tissue (48). Combining the various techniques holds promise for personalized thymus regeneration approaches.